Search
Acute Ischemic Stroke Clinical Trials
A listing of 13 Acute Ischemic Stroke clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 13 of 13
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Acute Ischemic Stroke
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 13 active clinical trials seeking participants for Acute Ischemic Stroke research studies. The states with the highest number of trials for Acute Ischemic Stroke participants are Shandong, California, Beijing and Henan.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
Recruiting
NTS-104 TRIS will be administered as a single intravenous dose to healthy subjects at doses of 0.8, 4, 8 and 16 mg/kg in 4 Cohorts. Each cohort of 8 subjects will begin with dosing 2 sentinel subjects with one being given the investigational product and one the placebo. If no safety issues arise, dosing the remaining subjects in the cohort will begin. A Safety Review Committee will review the safety and pharmacokinetic data before approving escalation to the next dose level.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/24/2023
Locations: Parexel International EPCU Baltimore 7th floor, Baltimore, Maryland
Conditions: Acute Ischemic Stroke
13 - 13 of 13